PYC Therapeutics (ASX:PYC) - Prezzo delle azioni, notizie e analisi

PYC Panoramica delle azioni

PYC Therapeutics Limited, società di sviluppo di farmaci, è impegnata nella scoperta e nello sviluppo di nuovi farmaci a RNA per il trattamento di malattie genetiche in Australia. Maggiori dettagli

PYC analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	1/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 15.56% all'anno

Analisi del rischio

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Prezzo delle azioni volatile negli ultimi 3 mesi

PYC Therapeutics Limited Concorrenti

Actinogen Medical

ASX:ACW

AU$76.6m

Radiopharm Theranostics

ASX:RAD

AU$56.5m

Beroni Group

NSX:BTG

AU$75.9m

Orthocell

ASX:OCC

AU$150.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per PYC Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$1.79
Massimo di 52 settimane	AU$2.10
Minimo di 52 settimane	AU$0.73
Beta	0.60
1Variazione di 1 mese	-10.50%
Variazione a 3 mesi	70.48%
Variazione di 1 anno	135.53%
3Variazione a 3 anni	19.33%
Variazione a 5 anni	188.71%
Variazione dall'IPO	-31.15%

Notizie e aggiornamenti recenti

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Oct 25

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Rendimenti per gli azionisti

	PYC	AU Biotechs	AU Mercato
7D	-8.2%	-4.9%	0.4%
1Y	135.5%	9.9%	16.9%

Ritorno vs Industria: PYC ha superato il Australian Biotechs che ha restituito 9.9 % nell'ultimo anno.

Rendimento vs Mercato: PYC ha superato il mercato Australian che ha restituito 16.9 % nell'ultimo anno.

Volatilità dei prezzi

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement	12.4%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di PYC è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 12% ) di PYC è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Australian.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	n/a	Rohan Hockings	pyctx.com

PYC Therapeutics Limited, società di sviluppo di farmaci, è impegnata nella scoperta e nello sviluppo di nuovi farmaci a RNA per il trattamento di malattie genetiche in Australia. L'azienda offre VP-001, un programma farmacologico in fase 1 di sperimentazione clinica per il trattamento della retinite pigmentosa di tipo 11; PYC-001, un candidato farmaco per il trattamento di una malattia oculare accecante; PYC-002, un programma farmacologico per il trattamento di un grave disturbo dello sviluppo neurologico; e PYC-003, indicato per il trattamento della malattia policistica renale autosomica dominante. PYC Therapeutics Limited ha collaborazioni accademico-industriali con la Murdoch University per sostenere gli sforzi di scoperta e sviluppo di farmaci nel campo dei disturbi neurodegenerativi.

PYC Therapeutics Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di PYC Therapeutics con la sua capitalizzazione di mercato?
PYC statistiche fondamentali
Capitalizzazione di mercato	AU$863.23m
Guadagni(TTM)	-AU$37.73m
Ricavi(TTM)	AU$22.06m

37.9x

Rapporto P/S

-22.1x

Rapporto P/E

PYC è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PYC Conto economico (TTM)
Ricavi	AU$22.06m
Costo del fatturato	AU$0
Profitto lordo	AU$22.06m
Altre spese	AU$59.78m
Guadagni	-AU$37.73m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.081
Margine lordo	100.00%
Margine di profitto netto	-171.02%
Rapporto debito/patrimonio netto	0%

Come si è comportato PYC nel lungo periodo?

Vedi performance storica e confronto

PYC Panoramica delle azioni

Premi

Analisi del rischio

PYC Therapeutics Limited Concorrenti

ASX:ACW

AU$76.6m

ASX:RAD

AU$56.5m

NSX:BTG

AU$75.9m

ASX:OCC

AU$150.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

Recent updates

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

PYC Therapeutics Limited Riepilogo dei fondamenti

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy